Conference Series

Secondary title: 
Plasma copeptin as predictor of Cardio-renal disease
Dr. S. Enhörning
Conference Subtitle: 
Post doc at the department of Clinical Sciences at Lund University

Medical doctor at the department of Endocrinology at Skåne University Hospital in Lund, Sweden.

Dr. Sofia Enhörning graduated from medical school at Lund University and obtained her Ph.D degree in Internal Medicine at Lund University. Her research has focused on genetical and epidemiological studies of the vasopressin system and its links to metabolic disease. She is currently focusing on experimental intervention studies, investigating the role of hydration on the vasopressin system and gluco-regulatory hormones, and on epidemiological studies, investigating the links between the vasopressin marker copeptin and renal disease. Furthermore, she is investigating genetic predisposition for altered copeptin levels and will use a Mendelian Randomization approach to study if elevated copeptin is causally related with renal and cardiometabolic disease. Dr. Enhörning has received the Scandinavian Society for the Study of Diabetes (SSSD) Young Investigation Award and the ”best clinical diabetes thesis of the year” award in 2012 from the Swedish Society for Diabetology. In 2016, she was awarded with the Hydration and Kidney Health Grant.

Plasma copeptin as predictor of Cardio-renal disease

Vasopressin (VP), also known as antidiuretic hormone, is a vasopressor and antidiuretic peptide commonly known as an important operator in the salt and water regulation of the body. We and other groups recently established a link between the VP system and several cardiometabolic risk factors. Elevated VP, measured as copeptin (the C-terminal cleavage product of the VP precursor), predicts development of type 2 diabetes and abdominal obesity, and is an independent risk factor for diabetic heart disease and premature mortality. We are currently investigating effects of increased hydration on copeptin, glycemia and gluco-regulatory hormones.

Previous studies in humans and animals suggest a role for VP in renal function decline both in diabetes patients and in the general population. We are currently studying the link between copeptin and incident renal disease in large population based cohorts including the Malmö Diet and Cancer - Cardiovascular Cohort (n=5162) and the Malmö Preventive Project (n=5158). Copeptin is measured at baseline in the populations and disease is captured using nation-wide registers. Furthermore, we are planning a Mendelian Randomization study to test if VP (measured as copeptin) is causally related with renal and cardiometabolic disease. Susceptibility genes associated with altered copeptin levels will be identified using data from genome-wide association studies conducted in the Malmö Diet and Cancer - Cardiovascular Cohort, the Malmö Preventive Project, the FINRISK-97 cohort and the PREVEND cohort, followed by test of association with metabolic and cardiorenal disease in the DIAGRAM and CARDIOGRAM cohorts.

Our previous and current data suggest that copeptin is an independent predictor of cardiometabolic and renal diseases which can be used to identify individuals that are at higher risk for developing diabetes, renal disease and its cardiovascular complications in order to offer early preventive strategies.

Kidney Stones